Navigation Links
Orexigen(R) Therapeutics Appoints Wendy Dixon, Ph.D. to Board of Directors
Date:4/21/2010

o the risk and uncertainties inherent in the Orexigen business, including, without limitation: additional analyses of data from the Contrave Phase 3 trials and any other clinical trials of Contrave may produce negative or inconclusive results, or may be inconsistent with previously announced results or previously conducted clinical trials; the FDA may not agree with the Company's interpretation of efficacy and safety results; the FDA may require Orexigen to complete additional clinical, non-clinical or other requirements prior to the submission or the approval of NDA for Contrave; the third parties on whom Orexigen relies to assist with the development programs for Contrave, including clinical investigators, contract laboratories, clinical research organizations and manufacturing organizations, may not successfully carry out their contractual duties or obligations or meet expected deadlines, and the quality or accuracy of the data or materials generated by such third parties may be of insufficient quality to include in the Company's regulatory submissions; and other risks described in the Company's filings with the Securities and Exchange Commission. You are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date hereof, and Orexigen undertakes no obligation to revise or update this news release to reflect events or circumstances after the date hereof. All forward-looking statements are qualified in their entirety by this cautionary statement. This caution is made under the safe harbor provisions of Section 21E of the Private Securities Litigation Reform Act of 1995. All conclusions and determinations contained herein are subject to the Company's further analysis of the clinical data. The ultimate determination of the safety and efficacy of Contrave will be made by the FDA and other relevant regulatory authorities.


'/>"/>
SOURCE Orexigen Therapeutics, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3

Related medicine technology :

1. Orexigen(R) Initiates Second Phase IIb Empatic(TM) Trial on Schedule
2. Orexigen(R) Therapeutics Presents Data on Its Proprietary Formulation of Naltrexone Sustained Release (SR) Used in Contrave(R)
3. Orexigen(R) Therapeutics Announces Changes to Its Clinical Programs and Management Team
4. Orexigen(R) Therapeutics Schedules July 20, 2009 Teleconference and Webcast Discussion of Contrave(R) Phase 3 Results
5. Orexigen(R) Therapeutics Schedules September 30, 2009 Teleconference and Webcast to Discuss Phase 2b Trial Results From Second Obesity Drug Candidate, Empatic(TM)
6. Orexigen(R) Therapeutics Releases New Efficacy Data for Contrave(R) in Late Breaker Presentations at the 27th Annual Scientific Meeting of The Obesity Society
7. Orexigen(R) Therapeutics Announces Third Quarter 2009 Financial Results
8. Orexigen(R) Therapeutics to Speak at Lazard Capital Markets Healthcare Conference
9. Orexigen(R) Therapeutics Reports Inducement Grants Under NASDAQ Listing Rule 5635
10. Orexigen(R) Therapeutics Reports Inducement Grant Under NASDAQ Listing Rule 5635(c)(4)
11. Orexigen(R) Therapeutics Reports Inducement Grant Under NASDAQ Listing Rule 5635(c)(4)
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/17/2014)... , Oct. 17, 2014 UBM Medica US announces ... leading online community and information resource for neurologists and other ... and Alzheimer disease , with discussions of the latest ... 1 million Americans have Parkinson disease , more than the ... Lou Gehrig disease. Diagnosis can be difficult because ...
(Date:10/17/2014)... -- A victim of medical negligence at the hands of ... history of alcohol abuse, a physician and consumer advocates unveiled ... highlighting how Prop 46 will identify and deter physician substance ... The ad pictures a doctor drinking at a bar as ... will enact the first law in the nation requiring random ...
(Date:10/17/2014)... Inc ., reported on results of 59 glaucoma patients treated ... to 3 years with the InnFocus MicroShunt® at the 2014 ... . The Summit was held prior ... American Academy of Ophthalmology . The Company also said it ... countries by early 2015. Logo - http://photos.prnewswire.com/prnh/20141016/152617LOGO ...
Breaking Medicine Technology:Neurology Times Features Coverage of Parkinson and Alzheimer Disease 2Neurology Times Features Coverage of Parkinson and Alzheimer Disease 3Victim Of Negligence At Hands Of A Drunk Doctor, A Physician and Consumer Advocates Release New Yes on 46 TV Ad, "On Call" 2Victim Of Negligence At Hands Of A Drunk Doctor, A Physician and Consumer Advocates Release New Yes on 46 TV Ad, "On Call" 3Victim Of Negligence At Hands Of A Drunk Doctor, A Physician and Consumer Advocates Release New Yes on 46 TV Ad, "On Call" 4InnFocus Featured at the Ophthalmology Innovation Summit In Chicago 2
(Date:10/20/2014)... Myoderm announced today the ... their CentralSource service. Matthew will play ... drug sourcing, distribution, and management service for international ... of industry experience, in both business development and ... their international success to help clients manage their ...
(Date:10/20/2014)... Collins, CO (PRWEB) October 20, 2014 ... dGH assays are the only imaging assays capable ... in a single test.  With these three dimensions ... their ability to detect the widest range of ... translocations—mutations usually missed by other genomic tools, including ...
(Date:10/20/2014)... October 20, 2014 Unveiled at the Sept. ... Direction Scorecard conservatively estimates member hospital ROI on membership dues ... dues, The Center provides $12.50 in value to member hospitals. ... Value – Member Dues)/Member Dues. , “This is the ... number and we think the methodology is really sound,” said ...
(Date:10/20/2014)... Houston plastic surgeon Dr. Christopher Patronella ... his innovative True Form Tummy Tuck® method ... faculty at The University of Texas Medical Branch ... a medical student. Patronella, who is a founding partner ... practices in Texas, The Aesthetic Center for Plastic ...
(Date:10/19/2014)... The leading review website, Top10BestSEOHosting.com, has recently ... are the best Dedicated Server Hosting suppliers. Their ... to buy high quality hosting and save money ... of Top10BestSEOHosting.com says, “We believe that iPage and ... A lot of the global clients enjoy using ...
Breaking Medicine News(10 mins):Health News:Myoderm Hires Matthew Voicheck to Lead Turnkey Drug Sourcing Service 2Health News:KromaTiD Launches Genome Screening and Discovery Services 2Health News:KromaTiD Launches Genome Screening and Discovery Services 3Health News:Scorecard Estimates Hospital ROI at $12.50 for every $1 Spent on Dues 2Health News:Scorecard Estimates Hospital ROI at $12.50 for every $1 Spent on Dues 3Health News:Scorecard Estimates Hospital ROI at $12.50 for every $1 Spent on Dues 4Health News:Plastic Surgeon Patronella Presents Artistically-Inspired Tummy Tuck Method to Future Generation of Plastic Surgeons in Texas 2Health News:Top10BestSEOHosting.com Considers iPage And GreenGeeks As The Best Dedicated Server Hosting Suppliers 2
... ,KO Cancer, with Susan G. Komen for the Cure, ... boxers,Felix "Tito" Trinidad and Roy Jones Jr. -- who will ... Jan. 19 -- have teamed with Susan G.,Komen for the ... activists, to help educate and raise awareness regarding the,deadly disease., ...
... diagnostic imaging, BLOOMINGTON, Minn., Dec. 21 ... efficiency of care reduced,medical expenses by $74 million ... introduced in February, reduced unnecessary,tests by more than ... from the American College of Radiology to confirm ...
... BROOK, Ill. December 21, 2007 The ... for the role of endoscopy in treating dyspepsia, discomfort ... a fourth of the population in Western countries. ... instrument to evaluate the inside of the esophagus, stomach ...
... for 2007, CONCORD, Ontario, Dec. 21 ... ,OTG, ,the Company,), a,leading multi- industry computer hardware, ... received an order for 100TB SAN dedicated,to pioneering ... oncology hospitals. The EqualLogic iSCSI SAN order is ...
... HLS ) announced today that its Board of Directors ... on its 6.5%,Series A Convertible Perpetual Preferred Stock, payable ... 2, 2008., About HealthSouth, HealthSouth is the ... states across the country and in,Puerto Rico, HealthSouth serves ...
... by Dr. Steve Bailey, an internationally recognized sports historian, ... the beginnings, achievements and events that shaped the Paralympic ... Movement and other able-bodied sports. , In addition ... First establishes key players in administration and sports politics, ...
Cached Medicine News:Health News:Don King Enlists Prizefighters Felix 'Tito' Trinidad and Roy Jones Jr. to Strike a Blow against Breast Cancer 2Health News:Don King Enlists Prizefighters Felix 'Tito' Trinidad and Roy Jones Jr. to Strike a Blow against Breast Cancer 3Health News:HealthPartners Reports 2007 Most Cost Effective Programs Reduce Expenses by $74 Million 2Health News:ASGE offers guidelines on endoscopic treatment of dyspepsia 2Health News:ASGE offers guidelines on endoscopic treatment of dyspepsia 3Health News:On The Go Ships 100TB Hardware Order for Ground-Breaking Cancer Imaging and Therapy Projects 2Health News:On The Go Ships 100TB Hardware Order for Ground-Breaking Cancer Imaging and Therapy Projects 3Health News:HealthSouth Declares Dividend on 6.5% Series A Convertible Perpetual Preferred Stock 2Health News:First reputable book on the history of the Paralympic Movement 2
All-silicone construction provides maximum softness and biocompatibility for enhanced patient comfort. Supplied sterile in peel-open packages. Intended for one-time use....
The 100% Silicone construction is ideal for pediatric and latex-sensitive patients....
BARDEX Red Rubber Urethral Catheter (Robinson Model)...
Used for injection into urethral strictures, bladder neck contracture, and the bladder wall. Supplied sterile in peel-open packages. Intended for one-time use....
Medicine Products: